EcoR1 Capital, LLC
- SEC CIK
- 0001587114
- Latest filing
- Aug 14, 2026
Holdings in Q3 2021
Holdings as of Sep 30, 2021, filed Nov 22, 2021. Long positions only; changes compare share counts with Q2 2021.
- Positions
- 69
- −3 vs. Q2 2021
- Portfolio value
- $2.83B
- +$166.4M (+6.2%) vs. Q2 2021
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| PRTAProthena Corp Public Ltd Co | SHS | 11,284,280 | $803.8M | 28.4% | 00.0% | Unchanged | History |
| MORFMorphic Holding, Inc. | COM | 3,951,566 | $223.8M | 7.9% | 00.0% | Unchanged | History |
| ANABAnaptysbio, Inc | COM | 7,521,024 | $204.0M | 7.2% | 00.0% | Unchanged | History |
| RCUSArcus Biosciences, Inc. | COM | 5,122,359 | $178.6M | 6.3% | +1,787,112+53.6% | Added | History |
| XNCRXencor Inc | COM | 4,906,106 | $160.2M | 5.7% | 00.0% | Unchanged | History |
| NUVBNuvation Bio Inc. | COM CL A | 13,711,517 | $136.3M | 4.8% | 00.0% | Unchanged | History |
| ALECAlector, Inc. | COM | 4,994,970 | $114.0M | 4.0% | +752,336+17.7% | Added | History |
| MRTXMirati Therapeutics, Inc. | COM | 464,298 | $82.1M | 2.9% | 00.0% | Unchanged | History |
| LKFTLakefront Biotherapeutics NV | SPON ADR | 1,558,749 | $82.0M | 2.9% | +1,558,749 | New | History |
| STTKShattuck Labs, Inc. | COM | 3,709,072 | $75.6M | 2.7% | +390,662+11.8% | Added | History |
| ORICOric Pharmaceuticals, Inc. | COM | 3,468,944 | $72.5M | 2.6% | +376,726+12.2% | Added | History |
| KURAKura Oncology, Inc. | COM | 3,724,437 | $69.8M | 2.5% | 00.0% | Unchanged | History |
| Avidity Biosciences, Inc.05370A108 | COM | 2,759,505 | $68.0M | 2.4% | +655,555+31.2% | Added | – |
| GRTSGritstone bio, Inc. | COM | 5,560,748 | $60.1M | 2.1% | +2,139,461+62.5% | Added | History |
| RLAYRelay Therapeutics, Inc. | COM | 1,385,276 | $43.7M | 1.5% | −3,102,500−69.1% | Reduced | History |
| ITOSiTeos Therapeutics, Inc. | COM | 1,303,157 | $35.2M | 1.2% | +267,293+25.8% | Added | History |
| NRIXNurix Therapeutics, Inc. | COM | 1,126,640 | $33.8M | 1.2% | −841,310−42.8% | Reduced | History |
| JANXJanux Therapeutics, Inc. | COM | 1,411,975 | $30.5M | 1.1% | 00.0% | Unchanged | History |
| DSGNDesign Therapeutics, Inc. | COM | 1,863,098 | $27.4M | 1.0% | +603,079+47.9% | Added | History |
| PTGXProtagonist Therapeutics, Inc | COM | 1,443,800 | $25.6M | 0.9% | +1,443,800 | New | History |
| DRNADicerna Pharmaceuticals Inc | COM | 1,249,812 | $25.2M | 0.9% | +1,249,812 | New | History |
| AKUSAkouos, Inc. | COM | 1,975,984 | $22.9M | 0.8% | 00.0% | Unchanged | History |
| SLDBSolid Biosciences Inc. | COM | 9,202,702 | $22.0M | 0.8% | 00.0% | Unchanged | History |
| EWTXEdgewise Therapeutics, Inc. | COM | 1,279,175 | $21.2M | 0.8% | +55,000+4.5% | Added | History |
| OVIDOvid Therapeutics Inc. | COM | 6,082,200 | $20.4M | 0.7% | 00.0% | Unchanged | History |
| TNGXTango Therapeutics, Inc. | COM | 1,300,000 | $16.8M | 0.6% | +1,300,000 | New | History |
| BLUEbluebird bio, Inc. | COM | 802,507 | $15.3M | 0.5% | +802,507 | New | History |
| ERASErasca, Inc. | COM | 700,000 | $14.9M | 0.5% | +700,000 | New | History |
| CNTACentessa Pharmaceuticals plc | SPONSORED ADS | 754,545 | $12.6M | 0.4% | 00.0% | Unchanged | History |
| SPRYARS Pharmaceuticals, Inc. | COM | 1,184,710 | $11.8M | 0.4% | −1,433,326−54.7% | Reduced | History |
| ODTOdonate Therapeutics, Inc. | COM | 3,727,261 | $10.8M | 0.4% | +2,896,061+348.4% | Added | History |
| CRVSCorvus Pharmaceuticals, Inc. | COM | 2,081,077 | $10.1M | 0.4% | −1,498,300−41.9% | Reduced | History |
| IMVTImmunovant, Inc. | COM | 1,140,819 | $9.91M | 0.4% | +1,140,819 | New | History |
| CCCCC4 Therapeutics, Inc. | COM STK | 200,000 | $8.94M | 0.3% | 00.0% | Unchanged | History |
| KRONKronos Bio, Inc. | COM | 387,357 | $8.12M | 0.3% | 00.0% | Unchanged | History |
| NGNENeurogene Inc. | COM | 860,619 | $6.22M | 0.2% | −1,498,185−63.5% | Reduced | History |
| FLACFrazier Lifesciences Acquisition Corp | CL A SHS | 587,615 | $5.77M | 0.2% | +387,120+193.1% | Added | History |
| ACIUAC Immune SA | SHS | 751,251 | $5.04M | 0.2% | −1,896,912−71.6% | Reduced | History |
| KRSAKorsana Biosciences, Inc. | COM | 1,606,276 | $4.93M | 0.2% | 00.0% | Unchanged | History |
| JYACJiya Acquisition Corp. | COM CL A | 500,000 | $4.88M | 0.2% | 00.0% | Unchanged | History |
| VERVVerve Therapeutics, Inc. | COM | 100,000 | $4.70M | 0.2% | 00.0% | Unchanged | History |
| KNTEKinnate Biopharma Inc. | COM | 175,000 | $4.03M | 0.1% | +150,000+600.0% | Added | History |
| OBIOOrchestra BioMed Holdings, Inc. | ORD SHS | 400,000 | $3.96M | 0.1% | 00.0% | Unchanged | History |
| FS Development Corp II30318F100 | COM CL A | 371,014 | $3.69M | 0.1% | +221,014+147.3% | Added | – |
| DYNDyne Therapeutics, Inc. | COM | 215,000 | $3.57M | 0.1% | 00.0% | Unchanged | History |
| IGMSIGM Biosciences, Inc. | COM | 38,030 | $2.50M | 0.1% | 00.0% | Unchanged | History |
| FMTXForma Therapeutics Holdings, Inc. | SHS | 90,141 | $2.09M | 0.1% | −15,497−14.7% | Reduced | History |
| BCLS Acquisition CorpG0904B105 | COM CL A | 200,000 | $1.99M | 0.1% | 00.0% | Unchanged | – |
| MLTXMoonLake Immunotherapeutics | COM CL A | 200,000 | $1.99M | 0.1% | 00.0% | Unchanged | History |
| 5 01 Acquisition Corp33836P105 | COM CL A | 200,000 | $1.96M | 0.1% | 00.0% | Unchanged | – |
| Eucrates Biomedical Acqu CorG3141W106 | SHS | 200,000 | $1.96M | 0.1% | 00.0% | Unchanged | – |
| BOLTBolt Biotherapeutics, Inc. | COM | 150,000 | $1.85M | 0.1% | 00.0% | Unchanged | History |
| CRBUCaribou Biosciences, Inc. | COM | 75,000 | $1.79M | 0.1% | +75,000 | New | History |
| ARYDARYA Sciences Acquisition Corp IV | CL A | 150,000 | $1.51M | 0.1% | 00.0% | Unchanged | History |
| PMVPPMV Pharmaceuticals, Inc. | COM | 50,000 | $1.49M | 0.1% | 00.0% | Unchanged | History |
| BCABBioAtla, Inc. | COM | 50,000 | $1.47M | 0.1% | 00.0% | Unchanged | History |
| RPTXRepare Therapeutics Inc. | COM | 50,000 | $1.29M | <0.1% | 00.0% | Unchanged | History |
| MGTXMeiraGTx Holdings plc | COM | 94,819 | $1.25M | <0.1% | 00.0% | Unchanged | History |
| VYGRVoyager Therapeutics, Inc. | COM | 445,992 | $1.17M | <0.1% | +445,992 | New | History |
| Turmeric Acquisition CorpG9127T108 | CL A | 100,000 | $979.0K | <0.1% | 00.0% | Unchanged | – |
| Omega Alpha SpacG6749V107 | CL A | 50,000 | $487.0K | <0.1% | 00.0% | Unchanged | – |
| SRRKScholar Rock Holding Corp | COM | 8,208 | $271.0K | <0.1% | +8,208 | New | History |
| ALPNAlpine Immune Sciences, Inc. | COM | 7,001 | $75.0K | <0.1% | −515,634−98.7% | Reduced | History |
| Nuvation Bio Inc.67080N119 | *W EXP 07/07/202 | 963,333 | – | – | 00.0% | Unchanged | – |
| Eucrates Biomedical Acqu CorG3141W122 | *W EXP 10/23/202 | 66,666 | – | – | 00.0% | Unchanged | – |
| Frazier Lifesciences Acqu CoG3710A113 | *W EXP 11/30/202 | 66,665 | – | – | 00.0% | Unchanged | – |
| Turmeric Acquisition CorpG9127T124 | *W EXP 10/08/202 | 33,333 | – | – | 00.0% | Unchanged | – |
| CareMax, Inc.14171W111 | *W EXP 06/08/202 | 100,000 | – | – | 00.0% | Unchanged | – |
| Surrozen, Inc.86889P117 | *W EXP 08/01/203 | 66,665 | – | – | +66,665 | New | – |
Options (2)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.
Sold out since Q2 2021 (14)
Positions held at the end of Q2 2021 that are gone from this filing.
| Security | Class | Shares in Q2 2021 | Value in Q2 2021 | % of portfolio in Q2 2021 | History |
|---|---|---|---|---|---|
| Translate Bio, Inc.89374L104 | COM | 1,048,976 | $28.9M | 1.1% | – |
| KYMRKymera Therapeutics, Inc. | COM | 519,416 | $25.2M | 0.9% | History |
| ARVNArvinas, Inc. | COM | 321,724 | $24.8M | 0.9% | History |
| BCELAtreca, Inc. | CL A COM | 2,426,685 | $20.7M | 0.8% | History |
| KDNYChinook Therapeutics, Inc. | COM | 931,650 | $13.2M | 0.5% | History |
| ZNTLZentalis Pharmaceuticals, Inc. | COM | 200,000 | $10.6M | 0.4% | History |
| BCTG Acquisition Corp05492W103 | COM | 800,000 | $9.10M | 0.3% | – |
| KLRSKalaris Therapeutics, Inc. | COM | 447,012 | $8.82M | 0.3% | History |
| SYRSSyros Pharmaceuticals, Inc. | COM | 1,000,000 | $5.45M | 0.2% | History |
| DNTHDianthus Therapeutics, Inc. | COM | 366,867 | $3.59M | 0.1% | History |
| NGMNGM Biopharmaceuticals Inc | COM | 143,567 | $2.83M | 0.1% | History |
| Consonance HFW Acquisition CG2445M103 | SHS CL A | 200,000 | $1.99M | 0.1% | – |
| FSTXF-star Therapeutics, Inc. | COM | 46,000 | $395.0K | <0.1% | History |
| Consonance HFW Acquisition CG2445M111 | *W EXP 10/28/202 | 66,665 | – | – | – |